Research Article
The Mechanisms of the Regulation of Immune Response in Patients with Comorbidity of Chronic Obstructive Pulmonary Disease and Asthma
Table 2
Parameters of immune status in patients with COPD, asthma, and ACOS.
| | Parameters | Control,
(group 1) | COPD,
(group 2) | Asthma,
(group 3) | Comorbid COPD and asthma (ACOS),
(group 4) |
| | Leukocytes, 109/L | 5.66 (4.75–7.25) | 7.90 (7.40–8.30)
| 5.57 (5.40–5.80)
| 6.24 (5.90–6.40)
|
| | Lymphocytes | | | | | | % | 31.09 (27.15–32.55) | 29.30 (29.00–30.00) | 31.92 (30.60–33.10) | 36.33 (34.40–38.80)
| | Absolute | 1727.73 (1331.90–2034.50) | 2313.89 (2227.40–2407.00)
| 1776.05 (1722.60–1820.00)
| 2269.18 (2029.60–2483.20)
|
| | CD3+ | | | | | | % | 70.62 (66.71–72.40) | 84.62 (80.73–88.83)
| 63.25 (59.18–67.06)
| 70.46 (62.00–79.39)
| | Absolute | 1217.72 (960.13–1495.18) | 1956.25 (1836.80–2010.58)
| 1122.72 (1088.11–1189.37)
| 1584.06 (1539.58–1611.29)
|
| | CD3+CD4+ | | | | | | % | 44.47 (41.42–47.31) | 60.14 (58.00–61.04)
| 40.78 (39.80–42.00)
| 40.81 (39.32–41.41)
| | Absolute | 763.13 (634.98–960.84) | 1385.75 (1334.81–1432.19)
| 723.47 (709.80–736.09) | 926.16 (840.46–993.28)
|
| | CD3+CD8+ | | | | | | % | 24.65 (21.86–26.01) | 25.22 (24.65–26.60) | 18.99 (18.58–19.40)
| 27.24 (26.20–27.92)
| | Absolute | 426.83 (304.92–502.63) | 582.83 (539.84–621.88)
| 336.99 (327.71–343.53)
| 617.56 (565.04–673.18)
|
| | CD4+/CD8+ ratio | 2.01 (1.44–2.40) | 2.40 (2.32–2.46)
| 2.15 (2.11–2.17)
| 1.50 (1.44–1.51)
|
| | CD19+ | | | | | | % | 12.00 (9.22–14.78) | 10.31 (9.22–11.10) | 20.26 (19.36–20.83)
| 19.04 (17.69–20.650)
| | Absolute | 203.33 (159.45–258.77) | 237.87 (212.94–242.70) | 359.91 (340.66–385.92)
| 433.25 (376.49–496.64)
|
| | CD16+CD56+ | | | | | | % | 15.09 (10.95–18.27) | 14.08 (13.03–15.03) | 12.07 (11.00–12.68)
| 19.05 (18.22–20.04)
| | Absolute | 257.86 (209.69–328.41) | 328.75 (301.981–349.13) | 215.12 (189.73–220.99)
| 432.41 (394.35–472.85)
|
| | TNF-, pg/mL | 18.32 (13.49–22.11) | 48.51 (46.80–50.45)
| 40.29 (36.80–45.61)
| 48.24 (43.78–52.84)
|
| | IFN-, pg/mL | 59.17 (54.61–63.45) | 78.69 (71.33–86.07)
| 26.99 (24.70–29.38)
| 47.93 (46.13–49.45)
|
| | IL-4, pg/mL | 56.41 (53.34–59.47) | 43.95 (41.58–47.09)
| 90.42 (84.25–94.25)
| 81.70 (74.55–87.35)
= 0.0001 |
| | IgE, pg/mL | 184.75 (160.00–215.00) | 200.04 (159.50–233.20) | 515.92 (437.00–581.00)
| 569.25 (499.40–619.30)
|
| | LTB4, pg/mL | 10.35 (8.00–12.50) | 18.00 (14.00–18.00)
| 50.53 (37.00–56.00)
| 86.75 (84.00–89.00)
= 0.002 |
| | ТХВ2, pg/mL | 15.87 (15.00–17.50) | 31.36 (31.00–32.00)
| 34.77 (34.00–36.00)
| 22.00 (19.00–24.50)
|
|
|
